Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis

Journal of Thrombosis and Thrombolysis

Volumn 36, Issue 3, 2013, Pages 223-232

  Chatterjee, Saurav ^a   Ghose, Abhimanyu ^b   Sharma, Abhishek ^a   Guha, Gunjan ^c   Mukherjee, Debabrata ^d   Frankel, Robert ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Anti platelets; Ischemia; Prasugrel; Ticagrelor

Indexed keywords

PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR MORTALITY; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LOADING DRUG DOSE; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; STENT THROMBOSIS; SYSTEMATIC REVIEW;

ADENOSINE; HEMORRHAGE; HUMANS; ISCHEMIA; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PUBMED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS; THIOPHENES; THROMBOSIS; TICLOPIDINE;

EID: 84884820847     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0838-z     Document Type: Conference Paper

References (43)

1. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32(23):2999-3054
2. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA et al (2006) Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 27(10):1166-1173
3. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ et al (2004) Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: The clopidogrel in unstable angina to prevent recurrent ischemic Events (CURE) Trial. Circulation 110(10):1202-1208
4. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001-2015
5. Michelson AD (2008) P2Y12 antagonism: Promises and challenges. Arterioscler Thromb Vasc Biol 28(3):s33-s38
6. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S et al (2010) Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 56(18):1456-1462
7. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045-1057
8. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B et al (2011) 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation 124(23):e574-e651
9. Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses. BMJ 326(7387):472
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med 6(7):e1000100
11. Higgins JPT, Green S (2008) Cochrane handbook for systematic reviews of interventions. Wiley, London
12. Donahoe SM, Sabatine MS (2005) Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy. Expert Rev Pharmacoecon Outcomes Res 5(6):751-761
13. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 288(19):2411-2420
14. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494-502
15. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116(7):e148-e304
16. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 110(5):588-636
17. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y et al (1994) The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 72(2):313-317
18. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E et al (2006) Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26(8):1895-1900
19. Gurbel PA, Bliden KP (2003) Durability of platelet inhibition by clopidogrel. Am J Cardiol 91(9):1123-1125
20. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45(2):246-251
21. Heptinstall S (2006) Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes. J Thromb Haemost 4(3):539-541
22. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA et al (2007) Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 49(14):1505-1516
23. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A et al (2009) Interindividual variability in the response to oral antiplatelet drugs: A position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 30(4):426-435
24. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B et al (2003) Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59(3):295-302
25. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM (2003) Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107(23):2908-2913
26. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I et al (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109(25):3171-3175
27. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T et al (2006) High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4(3):542-549
28. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA et al (2008) Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29(1):21-30
29. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H (2000) The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 129(7):1439-1446
30. Weerakkody GJ, Jakubowski JA, Brandt JT, Farid NA, Payne CD, Zhu J et al (2007) Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 100(2):331-336
31. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS et al (2007) A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153(1):66.e9-66.e16
32. Asai F, Jakubowski JA, Naganuma H, Brandt JT, Matsushima N, Hirota T et al (2006) Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans. Platelets 17(4):209-217
33. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD et al (2005) Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111(25):3366-3373
34. Husted S, van Giezen JJ (2009) Ticagrelor: The first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 27(4):259-274
35. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G (2006) Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 27(9):1038-1047
36. van Giezen JJ, Humphries RG (2005) Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 31(2):195-204
37. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G et al (2007) Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50(19):1844-1851
38. Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H et al (2010) Platelet inhibition and patient outcomes investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study. Lancet 375(9711):283-293
39. Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E, Sangiorgi G et al (2011) Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 150(3):325-331
40. Bellemain-Appaix A, Brieger D, Beygui F, Silvain J, Pena A, Cayla G et al (2010) New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: A meta-analysis. J Am Coll Cardiol 56(19):1542-1551
41. Kushner FG, Hand M, Smith SC Jr et al. (2009) American College of Cardiology Foundation/American Heart Association task force on practice guidelines 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update). A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines circulation, vol 120, pp 2271-2306
42. Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50(6):683-691
43. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM et al (2011) 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 57(19):e215-e367